Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.52), $0.37 better than the analyst estimate of ($1.89). Revenue for the quarter came in at $99.5 million versus the consensus estimate of $91.56 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.